<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1917">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04378712</url>
  </required_header>
  <id_info>
    <org_study_id>JT202005LZ</org_study_id>
    <nct_id>NCT04378712</nct_id>
  </id_info>
  <brief_title>Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19)</brief_title>
  <official_title>Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Institute of Respiratory Disease</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Institute of Respiratory Disease</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, multi-center, open-label clinical trial. Eligible patients were
      recruited from seven hospitals in China. On the basis of standard-of-care, patients in
      treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by
      using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd.,
      China) until discharge. Patients in control group received standard-of-care (consisting of
      oxygen therapy) alone until discharge.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, multi-center, open-label clinical trial. Eligible patients were
      recruited from seven hospitals in China. On the basis of standard-of-care, patients in
      treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by
      using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd.,
      China) until discharge. Patients in control group received standard-of-care (consisting of
      oxygen therapy) alone until discharge. Clinical assessments included the five-category
      ordinal scale, four-category ordinary scale of dyspnea, coughing, chest distress and chest
      pain (0: None; 1: Mild; 2: Moderate; 3: Severe; 4: Very severe) and adverse events, performed
      on admission, at enrollment, at day 2 and 3 after randomization, and the day before
      discharge. The primary endpoint was the proportion of patients with improved disease severity
      (by at least one scale). Secondary endpoints comprised the change from baseline in oxygen
      saturation and symptom scales.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Actual">March 23, 2020</completion_date>
  <primary_completion_date type="Actual">March 23, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with improved disease severity at day 2</measure>
    <time_frame>from baseline to day 2</time_frame>
    <description>The proportion of patients with improved disease severity (by at least one scale) at day 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of patients with improved disease severity at day 3</measure>
    <time_frame>from baseline to day 3</time_frame>
    <description>The proportion of patients with improved disease severity (by at least one scale) at day 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of patients with improved disease severity at the day before hospital discharge</measure>
    <time_frame>up to 14 days (from baseline to the day before hospital discharge)</time_frame>
    <description>The proportion of patients with improved disease severity (by at least one scale) at the day before hospital discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in oxygen saturation at day 2.</measure>
    <time_frame>from baseline to day 2</time_frame>
    <description>The change from baseline in oxygen saturation at day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in oxygen saturation at day 3.</measure>
    <time_frame>from baseline to day 3</time_frame>
    <description>The change from baseline in oxygen saturation at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in oxygen saturation at the day before hospital discharge</measure>
    <time_frame>up to 14 days (from baseline to the day before hospital discharge)</time_frame>
    <description>The change from baseline in oxygen saturation at the day before hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in dyspnea scale at day 2.</measure>
    <time_frame>from baseline to day 2</time_frame>
    <description>The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in dyspnea scale at day 3.</measure>
    <time_frame>from baseline to day 3</time_frame>
    <description>The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in dyspnea scale at the day before hospital discharge.</measure>
    <time_frame>up to 14 days (from baseline to the day before hospital discharge)</time_frame>
    <description>The change from baseline in dyspnea scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in cough scale at day 2</measure>
    <time_frame>from baseline to day 2</time_frame>
    <description>The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in cough scale at day 3</measure>
    <time_frame>from baseline to day 3</time_frame>
    <description>The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in cough scale at the day before hospital discharge</measure>
    <time_frame>up to 14 days (from baseline to the day before hospital discharge)</time_frame>
    <description>The change from baseline in cough scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in chest pain scale at day 2.</measure>
    <time_frame>from baseline to day 2</time_frame>
    <description>The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in chest pain scale at day 3.</measure>
    <time_frame>from baseline to day 3</time_frame>
    <description>The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in chest pain scale at the day before hospital discharge.</measure>
    <time_frame>up to 14 days (from baseline to the day before hospital discharge)</time_frame>
    <description>The change from baseline in chest pain scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in chest distress scale at day 2.</measure>
    <time_frame>from baseline to day 2</time_frame>
    <description>The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in chest distress scale at day 3.</measure>
    <time_frame>from baseline to day 3</time_frame>
    <description>The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in chest distress scale at the day before hospital discharge.</measure>
    <time_frame>up to 14 days (from baseline to the day before hospital discharge)</time_frame>
    <description>The change from baseline in chest distress scale (ranging from 0-4, with higher scores indicating severer outcomes) at the day before hospital discharge.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Covid-19</condition>
  <condition>Hydrogen/Oxygen Mixed Gas</condition>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H2-O2 (66% hydrogen; 33% oxygen) inhalation. Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Usual care referred to the standard-of-care (including oxygen therapy) recommended by Chinese National Health Commission.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrogen Oxygen Generator with Nebulizer</intervention_name>
    <description>Patients in treatment group inhaled H2-O2 (66% hydrogen; 33% oxygen) at 3 L/min via nasal cannula by using the Hydrogen/Oxygen Generator (model AMS-H-03, Shanghai Asclepius Meditech Co., Ltd., China) until discharge.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard-of-care</intervention_name>
    <description>Standard-of-care consisted of the supportive therapies (including oxygen therapy) recommended by the Chinese National Health Commission</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with lab-confirmed Covid-19 aged 18 to 75 years.

          -  Had dyspnea both on hospital admission and at enrollment.

          -  The patients volunteered to participate in this study and signed the informed consent

        Exclusion Criteria:

          -  Have other systemic diseases other than COVID-19 -- a disease that, according to the
             investigator's judgment, might increase the risk of developing adverse outcomes or
             affect the outcome measures after participation in the study.

        Women who are pregnant or breastfeeding or plan to be pregnant during the study.

        Subjects with one of the following respiratory diseases:

          -  Subjects in critical or unstable conditions. Critical (meeting any of the following
             symptoms): 1. Respiratory failure occurs and mechanical ventilation is needed; 2.
             Shock occurs; 3. Other organ failure, ICU monitoring and treatment is needed.

          -  Having immunosuppressive diseases (HIV), severe neurological disease affecting upper
             respiratory tract control, or other risk factors that the investigator believes can
             cause a significant risk of pneumonia in subjects.

          -  Subjects with mental disorder and cognitive impairment.

          -  Subjects who do not follow the study steps.

          -  Patients with mental retardation, poor motivation, drug abuse (including drugs and
             alcohol) or other disease history restricting the effectiveness of informed consent in
             this study.

          -  Use of antioxidants, including large doses of vitamin C and vitamin E.

          -  Subjects who are not suitable for participation in this study in the judgment of
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei-jie Guan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou Institute of Respiratory Disease</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.</citation>
    <PMID>32167524</PMID>
  </reference>
  <reference>
    <citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18. Erratum in: Lancet Respir Med. 2020 Feb 25;:.</citation>
    <PMID>32085846</PMID>
  </reference>
  <reference>
    <citation>Zhou ZQ, Zhong CH, Su ZQ, Li XY, Chen Y, Chen XB, Tang CL, Zhou LQ, Li SY. Breathing Hydrogen-Oxygen Mixture Decreases Inspiratory Effort in Patients with Tracheal Stenosis. Respiration. 2019;97(1):42-51. doi: 10.1159/000492031. Epub 2018 Sep 18.</citation>
    <PMID>30227423</PMID>
  </reference>
  <reference>
    <citation>Morgan SE, Vukin K, Mosakowski S, Solano P, Stanton L, Lester L, Lavani R, Hall JB, Tung A. Use of heliox delivered via high-flow nasal cannula to treat an infant with coronavirus-related respiratory infection and severe acute air-flow obstruction. Respir Care. 2014 Nov;59(11):e166-70. doi: 10.4187/respcare.02728. Epub 2014 Aug 12.</citation>
    <PMID>25118308</PMID>
  </reference>
  <reference>
    <citation>Kneyber MC, van Heerde M, Markhorst DG, Pl√∂tz FB. Mechanical ventilation with heliox decreases respiratory system resistance and facilitates CO2 removal in obstructive airway disease. Intensive Care Med. 2006 Oct;32(10):1676-7. Epub 2006 Aug 23.</citation>
    <PMID>16927073</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Institute of Respiratory Disease</investigator_affiliation>
    <investigator_full_name>Weijie Guan</investigator_full_name>
    <investigator_title>Associate professor of respiratory medicine, co-principal investigator</investigator_title>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>Hydrogen/oxygen mixed gas</keyword>
  <keyword>Dyspnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

